CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
February 05 2015 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT:CVM) announced that Geert
Kersten, Chief Executive Officer, will be presenting at the 17th
Annual BIO CEO & Investor Conference on Monday, February 9,
2015 at 4:00 p.m. Hosted by the Biotechnology Industry Organization
(BIO), the 17th Annual BIO CEO & Investor Conference will take
place February 9-10 at the Waldorf Astoria in New York City.
A live audio webcast of the presentation and replay will be
available under the investor relations section of CEL-SCI's website
at www.cel-sci.com. The replay of the presentation will be
available approximately 1 hours after the presentation and is
accessible until May 10, 2015.
About the BIO CEO & Investor Conference
The 17th Annual BIO CEO & Investor Conference is the largest
independent investor conference focused on publicly-traded
biotechnology companies. The conference is designed to foster an
informative dialogue between institutional investors and senior
biotechnology executives about emerging and current investment
opportunities. The 2014 CEO & Investor Conference featured
1,820 partnering meetings, 149 company presentations, and 1,400
attendees, over half of which were investors.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational immunotherapy Multikine (Leukocyte Interleukin,
Injection) is currently being studied in a pivotal Phase III
clinical trial against head and neck cancer. If the study endpoint,
which is a 10% improvement in overall survival of the subjects
treated with Multikine treatment regimen as compared to subjects
treated with current standard of care only is satisfied, the study
results will be used to support applications which will be
submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has recently
received a Phase I SBIR Grant from the National Institutes of
Health to develop LEAPS as a potential treatment for RA with
researchers from Rush University Medical Center in Chicago,
Illinois. The Company has operations in Vienna, Virginia, and
in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024